SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is experiencing extreme volatility as traders react to escalating geopolitical tensions in the Middle East, characterized by drone strikes and renewed hostilities. The community is actively debating whether ongoing reports of potential peace deals are genuine or merely market-manipulation tactics intended to suppress oil prices ahead of key economic events.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

The SPY is trending as market participants react to conflicting signals regarding geopolitical tensions in the Middle East and a purported peace deal, which many in the community view with skepticism. Traders are actively debating whether these developments represent a genuine shift in market dynamics or another example of speculative volatility driven by leadership rhetoric.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is trending as investors digest the company's recent strategic pivot into AI-driven drug discovery via a partnership with Anthropic and new clinical trial successes in oncology. The community is actively debating the stock's potential for a long-term turnaround as management works to navigate patent cliffs through a combination of pipeline innovation and targeted M&A.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is at the center of intense market focus as investors await earnings due after Monday's market close, with community sentiment divided between bullish anticipation of continued AI-driven revenue growth and concerns over high valuation. Traders are closely monitoring the stock's consolidation above key support levels, viewing the upcoming report as a critical catalyst that could determine whether the stock breaks out or faces further downside volatility.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending due to community optimism surrounding potential exchange re-listings and governance-led burn mechanisms, though debates persist over whether this marks a true revival or a speculative trap. Investors remain highly active in discussions regarding the project's long-term utility, regulatory catalysts, and the hope for a significant supply reduction.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

Cardano is trending amid intense community debate over its long-term viability, with many investors debating whether to accumulate at current lows or exit following recent security concerns and stagnant price performance. Discussions are heavily polarized between those betting on a potential resurgence fueled by legislative milestones and others dismissing the asset as a failing project due to its founder's public visibility and lack of institutional adoption.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is capturing significant community attention as investors anticipate a major revenue beat and potential pipeline updates following an upcoming earnings call, fueling widespread speculation about a possible acquisition. Market participants are actively discussing the stock's strong performance in the autoimmune space and the potential for a premium buyout, viewing recent price volatility as an opportunity for accumulation.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

Gold is currently trending as investors debate whether the recent pullback represents a major generational buying opportunity or the beginning of a multi-year downtrend. The community is actively discussing the impact of high interest rates, rising national debt, and geopolitical tensions, with many seeking confirmation of a bottom through technical support levels and volume patterns.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently trending as investors eagerly anticipate topline Phase 3 IZAR-1 data, with community discussion focused on whether an imminent clinical readout will coincide with quarterly earnings or a potential buyout. While management previously signaled a near-term disclosure timeline, retail sentiment remains mixed, balancing frustration over delayed catalysts against high conviction in the drug's best-in-class potential.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is experiencing significant market interest following a landmark agreement with the Trump administration to lower drug prices and expand U.S. manufacturing in exchange for a three-year tariff exemption. Investors are actively monitoring the stock's potential for sustained growth as management emphasizes long-term revenue targets and new pipeline developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript

Kura Oncology (NASDAQ:KURA) released first-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below.
This content is powered by Benzinga APIs. For comprehensive financial dataread more...

Kura Oncology (KURA) Reports Q1 Loss, Tops Revenue Estimates

Kura Oncology (KURA) delivered earnings and revenue surprises of +5.33% and +21.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of -6.88% and -98.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Will MeiraGTx Holdings PLC (MGTX) Report Negative Q1 Earnings? What You Should Know

MeiraGTx (MGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kura Oncology (KURA) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Kura Oncology (KURA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kura Oncology (KURA) Projected to Post Quarterly Earnings on Thursday

Kura Oncology (NASDAQ:KURA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-kura-oncology-inc-stock...

Moody Aldrich Partners LLC Buys New Position in Kura Oncology, Inc. $KURA

Moody Aldrich Partners LLC bought a new stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 179,728 shares of the company's s...

KURA Stock Rallies 8% on Strong Preliminary Renal Cancer Study Data

Kura Oncology shares jump 8% as FIT-001 data show strong tumor response and disease control with darlifarnib combination in pretreated renal cancer patients.

Kura Oncology (KURA) Moves 8.3% Higher: Will This Strength Last?

Kura Oncology (KURA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Kura Oncology, Inc. (NASDAQ:KURA) Given Average Recommendation of "Moderate Buy" by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) has received an average recommendation of "Moderate Buy" from the thirteen brokerages that are currently covering the stock, MarketBeat reports...

$KURA Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.83 down -25.76% YoY
• Reported revenue of $18.27M up 29.47% YoY
• Kura Oncology expects its $580.8M in cash, plus $180M in anticipated collaboration payments, to fund the ziftomenib AML program through topline KOMET-017 Phase 3 results anticipated in 2028.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

KURA Stock Pops After Promising Early Cancer Data — What Investors Should Know

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$9.01
Prev Close	$9.31
Open	$9.47
Dividend Yield	0.00%
50-Day Moving Average	$10.20
Beta	1.15
Avg. Volume	1.9M
PE Ratio	-2.69

52-Week High	$12.49
52-Week Low	$5.45
Market Capitalization	$799.86M
EPS (Annual)	-$3.18
Price to Book	7.41
Revenue Per Employee	$259,546.15

Feed

News

Sentiment

Earnings

Fundamentals

Info